Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac safety of Mitoxantrone Hydrochloride Liposome in advanced malignant tumors
NCT05089461Phase 2Suspended
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in advanced malignant solid tumor, peripheral T-cell lymphoma (PTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2022; status: suspended.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
advanced malignant solid tumorperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05089461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089461.